Next 10 |
2024-05-09 21:14:07 ET Clearside Biomedical, Inc. (CLSD) Q1 2024 Earnings Conference Call May 09, 2024 4:30 PM ET Company Participants Remy Bernarda - Investor Relations George Lasezkay - Chief Executive Officer Victor Chong - Chief Medical Officer Charlie De...
2024-05-09 16:52:18 ET More on Clearside Biomedical Clearside Biomedical, Inc. (CLSD) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Clearside Biomedical Historical earnings data for Clearside Biomedical Financial information for Clea...
- Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected Q3 2024 - - Strengthened Management Team and Board of Directors with Two Key Additions - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., May 09, 2024 (GL...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
2024-05-08 17:20:55 ET More on Clearside Biomedical Clearside Biomedical, Inc. (CLSD) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Clearside Biomedical Historical earnings data for Clearside Biomedical Financial information for Clea...
ALPHARETTA, Ga., May 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that George Lasezkay, Pharm.D., J.D., ...
ALPHARETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that its first quarter 2024 financia...
ALPHARETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that Anthony S. Gibney has been appo...
ALPHARETTA, Ga., April 02, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that George Lasezkay, Pharm.D., J.D....
2024-03-18 13:56:57 ET More on Clearside Biomedical Clearside Biomedical, Inc. (CLSD) Q4 2023 Earnings Call Transcript Clearside to sell 11.11M shares at $1.35 in registered direct offering Seeking Alpha’s Quant Rating on Clearside Biomedical Historica...
News, Short Squeeze, Breakout and More Instantly...
Clearside Biomedical Inc. Company Name:
CLSD Stock Symbol:
NASDAQ Market:
Clearside Biomedical Inc. Website:
The Dow Jones index closed higher by around 350 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concer...
- Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected Q3 2024 - - Strengthened Management Team and Board of Directors with Two Key Additions - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., May 09, 2024 (GL...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...